VXUS · Vanguard Total International Stock Index Fund
VXUS tracks the Total International Stock and returned +22.3% over the past year.
Key facts
Its ten largest equity positions
| Holding | Weight | |
|---|---|---|
| Taiwan Semiconductor Manufacturing Co Lt | 3.97% | |
| Samsung Electronics Co Ltd | 1.67% | |
| ASML Holding NV | 1.32% | |
| SK hynix Inc | 1.14% | |
| Tencent Holdings Ltd | 0.89% | |
| HSBC Holdings PLC | 0.74% | |
| Alibaba Group Holding Ltd | 0.69% | |
| Roche Holding AG | 0.68% | |
| AstraZeneca PLC | 0.67% | |
| Novartis AG | 0.67% |
Compare VXUS
Also against BIL, BINC, BITO, BND, BNDX, BOND, BOXX, BSV, BWET, CGBL, CGDV, CGGR, COWZ, CTA, DBMF, DFUS, DGRO, DGRW, DIA, DVY, DYNF, EDV, EEM, EFA, EMB, EMXC, EWJ, EWT, EWY, EWZ, EZU, FBCG, FDVV, FENI, FLKR, FNDX, FTEC, FXI, GARP, GDX, GLD, GLDM, GOVT, GRNY, HDV, HGER, HYG, HYMB, IALT, IAU, IBB, IDEV, IEF, IEFA, IEI, IEMG, IGIB, IGM, IGSB, IJH, IJR, IJS, IJT, ILF, INDA, ITOT, IUSB, IVV, IWB, IWC, IWD, IWF, IWM, IWO, IXUS, IYE, IYR, IYW, JAAA, JNK, KRE, LQD, LYTE, MAGS, MBB, MDY, MGK, MINT, MOAT, MTUM, MUB, NOBL, ONEQ, PDBC, PFF, PULS, PVAL, QQQ, QQQM, QUAL, RDVY, REMX, RSP, SCHB, SCHD, SCHF, SCHG, SCHH, SCHP, SCHX, SDY, SGOV, SHV, SHY, SIVR, SLV, SPHD, SPHQ, SPLG, SPMO, SPSB, SPY, SPYD, SPYG, TIP, TLT, URTH, USFR, USHY, USMV, USO, VB, VBIL, VBK, VBR, VCIT, VCLT, VCSH, VDC, VDE, VEA, VEU, VGIT, VGK, VGLT, VGSH, VGT, VHT, VIG, VLUE, VNQ, VO, VOE, VONG, VOO, VOOG, VOX, VPL, VPU, VT, VTEB, VTI, VTIP, VTV, VTWO, VUG, VUSB, VWO, VXF, VYM, VYMI, XBI, XHB, XLB, XLC, XLE, XLF, XLG, XLI, XLK, XLP, XLRE, XLU, XLV, XLY, XOP, XOVR, XRT.
Period by period
| Window | Total return | S&P 500 | Gap to S&P 500 | Gap to Nasdaq-100 |
|---|---|---|---|---|
| 3 months | +2.2% | +3.3% | −1.1 pts | +3.0 pts |
| 6 months | +14.2% | +16.0% | −1.8 pts | −6.5 pts |
| 1 year | +22.3% | +17.5% | +4.8 pts | −0.7 pts |
| 3 years | +72.7% | +77.9% | −5.2 pts | −22.4 pts |
| Since listing | +179.9% | +687.0% | −507.1 pts | −1186.9 pts |
In plain words
VXUS is an index equity fund tracking the Total International Stock. Over the year to Sep 11, 2026 it returned +22.3% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.05% a year. By its holdings filed for Apr 30, 2026, 0% of the fund by weight is stocks the S&P 500 also holds, across 8775 positions, with the top ten at 12.4%.
| What it tracks | Total International Stock |
|---|---|
| Fund type | Index equity fund |
| Expense ratio (485BPOS XBRL, Feb 27, 2026) | 0.05% |
| Price | $87.14 |
| Listed since | Jan 28, 2011 |
| Net assets (SEC filing, whole fund, as filed for Apr 30, 2026) | $629.1bn |
| Below its high (ETFIQ) | −1.4% |
| Holdings | 8775 |
| Top ten weight | 12.4% |
| Holdings as of (SEC N-PORT) | Apr 30, 2026 |
| Already in the S&P 500, by weight (ETFIQ) | 0.0% |
| Active share vs the S&P 500 (ETFIQ) | 100.0% |
| Already in the Nasdaq-100, by weight (ETFIQ) | 0.7% |
Questions people ask
- How has VXUS performed?
- Over the year to Sep 11, 2026, VXUS returned +22.3% with distributions reinvested, against +17.5% for the S&P 500. Over three years the figure is +72.7%.
- What does VXUS cost?
- The prospectus expense ratio is 0.05% a year.
- What does VXUS hold?
- 8775 positions as filed for Apr 30, 2026, with the top ten at 12.4% of the fund. 0% of its weight is in stocks the S&P 500 also holds.
- How far is VXUS below its high?
- 1.4% below its high of Sep 4, 2026, measured on the reinvested series to Sep 11, 2026.
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Funds near this one
Cite this page. ETFIQ, VXUS, core index fund, data as of Sep 11, 2026. https://etfiq.com/funds/VXUS Free to use with attribution; the underlying files are at Open data.
ETFIQ covers leveraged and inverse, thematic, buffer, option-income, core index and spot crypto ETFs. This fund is here because the other funds here are measured against it and portfolios hold it. ETFIQ is an independent publisher and makes no recommendations. Standards and sources